Beam raises $135M series B

By raising a $135 million series B round on Wednesday, base editing company Beam Therapeutics has surpassed CRISPR Therapeutics AG (NASDAQ:CRSP) for the most venture money raised by a CRISPR-based company. Added to its May series A, Beam has now raised $222 million and plans to deploy the funds to advance a broader portfolio of gene-editing programs...